NCT00262028已完成2 期
A Phase 2, Randomized, Single-blind, Controlled, Single-Center Study to Compare the Safety and Immunogenicity of One Dose of Chiron Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Polysaccharide Vaccine Administered to Healthy Children 2-10 Years of Age and an Open-label Study to Assess the Safety and Immunogenicity of One Dose of Chiron Meningococcal ACWY Conjugate Vaccine Administered to Healthy Toddlers 12-23 Months of Age
Novartis Vaccines1 个研究点 分布在 1 个国家目标入组 910 人开始时间: 2005年4月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 910
- 试验地点
- 1
- 主要终点
- Number of Subjects (2-10 Years of Age) With Human Serum Bactericidal Activity (hSBA) Titers ≥1:4 After Receiving Either MenACWY-CRM or MenACWY-PS Vaccine
研究概览
简要总结
The purpose of this study is to evaluate the safety and immunogenicity of Novartis (formerly Chiron) Meningococcal ACWY Conjugate Vaccine administered to healthy children ages 1 - 10 years
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single
入排标准
- 年龄范围
- 12 Months 至 10 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Group 1: Healthy children 2-10 years of age;
- •Group 2: Healthy toddlers 12-23 months of age; who are up to date with age appropriate immunizations for diphtheria, tetanus, pertussis, polio, hepatitis B, Hemophilus influenzae type b, and pneumococcus.
排除标准
- •Group 1: Subjects with a previous or suspected disease caused by N. meningitidis; or previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s); Any serious acute, chronic or progressive disease.
- •Group 2: Subjects with a previous or suspected disease caused by N. meningitidis or previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s); Any serious acute, chronic or progressive disease.
研究组 & 干预措施
MenACWY-CRM (2-10 years)
Experimental
Subjects received one dose of investigational MenACWY-CRM conjugate vaccine
干预措施: MenACWY-CRM Vaccine (Biological)
MenACWY-CRM (12-23 months)
Experimental
Subjects received one dose of investigational MenACWY-CRM conjugate vaccine
干预措施: MenACWY-CRM Vaccine (Biological)
MenACWY-PS (2-10 years)
Active Comparator
Subjects received one dose of licensed comparator MenACWY polysaccharide (MenACWY-PS) vaccine
干预措施: MenACWY-PS Vaccine (Biological)
MenACWY-CRM+PnC (12-15 months)
Experimental
Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with PnC
干预措施: MenACWY-CRM Vaccine (Biological)
MenACWY-CRM+DTaP (16-23 months)
Experimental
Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with DTaP
干预措施: MenACWY-CRM Vaccine (Biological)
结局指标
主要结局
Number of Subjects (2-10 Years of Age) With Human Serum Bactericidal Activity (hSBA) Titers ≥1:4 After Receiving Either MenACWY-CRM or MenACWY-PS Vaccine
时间窗: 1 month post vaccination (Day 29)
Number of subjects (2-10 years of age) achieving with hSBA titers ≥1:4 against Neisseria meningitidis serogroups A,C,W and Y, one month after receiving one dose of either MenACWY-CRM vaccine or MenACWY-PS vaccine.
次要结局
- Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination in Children Aged 2 to 10 Years(Day 1 to 7 post vaccination)
- Number of Subjects Reporting Unsolicited Adverse Events After Vaccination in Toddlers Aged 12 to 23 Months(Day 1- Day 360 (Throughout the study))
- Percentages of Subjects (2-5 Years of Age and 6-10 Years of Age) With hSBA ≥ 1:4 After Receiving Either MenACWY-CRM or MenACWY-PS Vaccine(1 month post vaccination (Day 29))
- Percentages of Subjects (12-23 Months Old) With hSBA Titer ≥ 1:4 After Receiving MenACWY-CRM Vaccine Compared With Percentage of Subjects (3-5 Years Old) With hSBA Titer ≥ 1:4 After Receiving MenACWY-PS Vaccine(1 month post vaccination (Day 29))
- hSBA Geometric Mean Titer (GMT) in Subjects (12-23 Months Old) After Receiving MenACWY-CRM Vaccine Compared With hSBA GMT in 3-5 Year Old Subjects After Receiving MenACWY-PS Vaccine(1 month post vaccination (Day 29))
- hSBA Geometric Mean Titer (GMT) in Subjects (2-10 Years, 2-5 Years and 6-10 Years Old) After Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine(12 months post vaccination (Day 360))
- hSBA Geometric Mean Titer (GMT) in Subjects (2-10 Years of Age) After Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine(1 month post vaccination (Day 29))
- hSBA GMT in Subjects (2-5 Years of Age and 6-10 Years of Age) Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine(1 month post vaccination (Day 29))
- Number of Subjects (2-10 Years, 2-5 Years and 6-10 Years Old) With hSBA ≥ 1:4 After Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine(12 months post vaccination (Day 360))
- Number of Subjects Reporting Unsolicited Adverse Events (AEs) After Vaccination in Children Aged 2 to 10 Years(Day 1- Day 360 (throughout the study))
- Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination in Toddlers Aged 12 to 23 Months(Day 1 to 7 post vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk AdultsMeningococcal DiseaseNCT00560313Novartis Vaccines54
已完成
2 期
Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy ToddlersMeningococcal DiseaseMeningococcal MeningitisNCT01434680Novartis992
已完成
3 期
Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.Meningococcal DiseaseNCT01973218Novartis Vaccines264
已完成
2 期
Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy AdolescentsPrevention of Meningococcal DiseaseNCT00262041Novartis Vaccines524
已完成
2 期
Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination SchedulesMeningococcal DiseaseNCT00661713Novartis Vaccines1,631